Bupropion reduces some of the symptoms of marihuana withdrawal in chronic marihuana users: A pilot study

Substance Abuse: Research and Treatment

Volumn 6, Issue 1, 2012, Pages 63-71

  Penetar, David M ^a,b   Looby, Alison R ^a   Ryan, Elizabeth T ^a   Maywalt, Melissa A ^a   Lukas, Scott E ^a,b  

^a MCLEAN HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Bupropion; Cognitive performance; Marihuana; Pharmacotherapy; Sleep; Withdrawal

Indexed keywords

AMFEBUTAMONE; PLACEBO;

ADULT; ARTICLE; BECK DEPRESSION INVENTORY; CANNABIS ADDICTION; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DEPENDENCE TREATMENT; DRUG DOSE COMPARISON; DRUG EFFICACY; FEMALE; HUMAN; MALE; MENTAL PERFORMANCE; MORNING DOSAGE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; SLEEP PATTERN; SLEEP TIME; SOCIAL SUPPORT; WITHDRAWAL SYNDROME;

EID: 84864090544     PISSN: None     EISSN: 11782218     Source Type: Journal    
DOI: 10.4137/SART.S9706     Document Type: Article

References (37)

1. Jones RT, Benowitz NL, Herning RI. Clinical relevance of cannabis tolerance and dependence. J Clin Pharmacol. 1981;21(Suppl 8-9):143S-1452.
2. Tennant FS. The clinical syndrome of marijuana dependence. Psychiatric Annals. 1986;16:225-234.
3. Budney AJ, Moore BA, Vandrey RG, Hughes JR. The time course and significance of cannabis withdrawal. J Abnorm Psychol. 2003;112(3):393-402.
4. Kouri EM, Pope HG. Abstinence symptoms during withdrawal from chronic marijuana use. Exp Clin Psychopharmacol. 2000;8(4):483-492.
5. Budney AJ, Hughes JR, Moore BA, Novy PL. Marijuana abstinence effects in marijuana smokers maintained in their home environment. Arch Gen Psychiatry. 2001;58(10):917-24.
6. Budney AJ, Novy PL, Hughes JR. Marijuana withdrawal among adults seeking treatment for marijuana dependence. Addiction. 1999;94(9):1311-1322.
7. Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW. Abstinence symptoms following smoked marijuana in humans. Psychopharmacology (Berl). 1999;141(4):395-404.
8. Haney M, Ward AS, Comer SD, Hart CL, Foltin RW, Fischman MW. Bupropion SR worsens mood during marijuana withdrawal in humans. Psychopharmacology (Berl). 2001;155(2):171-179.
9. First MB, Gibbon M, Spitzer RL, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders (Research Version) 2002, NY: Biometrics Research, NY State Psychiatric Institute.
10. Carskadon MA, Dement WC, Mitler MM, Guilleminault C, Zarcone VP, Spiegel R. Self-reports versus sleep laboratory findings in 122 drug-free subjects with complaints of chronic insomnia. Am J Psychiatry. 1976;133(12): 1382-1388.
11. Baddeley AD. A 3-minute reasoning test based on grammatical transformations. Psychon Sci. 1968;10:341-342.
12. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561-571.
13. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988;56(6): 893-897.
14. DiClemente CC, Hughes SO. Stages of change profiles in outpatient alcoholism treatment. J Subst Abuse. 1990;2(2):217-235.
15. Sadeh A, Alster J, Urbach D, Lavie P. Actigraphically based automatic bedtime sleep wake scoring: Validity and clinical applications. J Ambulatory Monitoring. 1989;2:209-216.
16. Del Boca FK, Kranzler HR, Brown J, Korner PF. Assessment of medication compliance in alcoholics through UV light detection of a ribofavin tracer. Alcohol Clin Exp Res. 1996;20:1412-1417.
17. Huestis MA, Cone EJ. Differentiating new marijuana use from residual drug excretion in occasional marijuana users. J Anal Toxicol. 1998;22(6): 445-454.
18. Huestis MA, Mitchell JM, Cone EJ. Detection times of marijuana metabolites in urine by immunoassay and GC-MS. J Anal Toxicol. 1995;19(6):443-449.
19. Huestis MA, Mitchell JM, Cone EJ. Urinary excretion profiles of 11-nor-9-carboxy-delta 9-tetrahydrocannabinol in humans after single smoked doses of marijuana. J Anal Toxicol. 1996;20(6):441-452.
20. Steinberg KL, Roffman RA, Carroll KM, et al. Tailoring cannabis dependence treatment for a diverse population. Addiction. 2002;97 Suppl 1: 135-142.
21. Project MRG. Matching alcoholism treatments to client heterogeneity: Project Match posttreatment drinking outcomes. J Stud Alcohol. 1997;58:7-29.
22. Stephens RS, Babor TF, Kadden R, Miller M. The Marijuana Treatment Project: rationale, design and participant characteristics. Addiction. 2002; 97 Suppl 1:109-124.
23. Sinha R, Easton C, Renee-Aubin L, Carroll KM. Engaging young probation-referred marijuana-abusing individuals in treatment: a pilot trial. Am J Addict. 2003;12(4):314-323.
24. Bien TH, Miller WR, Tonigan JS. Brief interventions for alcohol problems: a review. Addiction. 1993;88(3):315-335.
25. Hurt RD, Sachs DP, Glover ED, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med. 1997;337(17): 1195-1202.
26. Jorenby D. Clinical efficacy of bupropion in the management of smoking cessation. Drugs. 2002;62 Suppl 2:25-35.
27. Vandrey RG, Budney AJ, Hughes JR, Liguori A. A within-subject comparison of withdrawal symptoms during abstinence from cannabis, tobacco, and both substances. Drug Alcohol Depend. 2008;92(1-3):48-54.
28. Vandrey RG, Budney AJ, Moore BA, Hughes JR. A cross-study comparison of cannabis and tobacco withdrawal. Am J Addict. 2005;14(1):54-63.
29. Carpenter KM, McDowell D, Brooks DJ, Cheng WY, Levin FR. A preliminary trial: Double-blind comparison of nefazodone, bupropion-SR, and placebo in the treatment of cannabis dependence. Am J Addict. 2009;18: 53-64.
30. Solowij N, Stephens RS, Roffman RA, et al. Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA. 2002;287(9): 1123-1131.
31. Pope HG, Gruber AJ, Hudson JI, Huestis MA, Yurgelun-Todd D. Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry. 2001;58(10):909-915.
32. Feinberg I, Jones R, Walker J, Cavness C, Floyd T. Effects of marijuana extract and tetrahydrocannabinol on electroencephalographic sleep patterns. Clin Pharmacol Ther. 1976;19(6):782-794.
33. Feinberg I, Jones R, Walker JM, Cavness C, March J. Effects of high dosage delta-9-tetrahydrocannabinol on sleep patterns in man. Clin Pharmacol Ther. 1975;17(4):458-466.
34. Karacan I, Fernandez-Salas A, Coggins WJ, et al. Sleep electroencephalographic-eletrooculographic characteristics of chronic marijuana users: Part I. Ann N Y Acad Sci. 1976;282:348-374.
35. Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW. Abstinence symptoms following oral THC administration to humans. Psychopharmacology (Berl). 1999;141(4):385-394.
36. Budney AJ, Higgins ST, Radonovich KJ, Novy PL. Adding voucher-based incentives to coping skills and motivational enhancement improves outcomes during treatment for marijuana dependence. J Consult Clin Psychol. 2000;68(6):1051-1061.
37. PDR, Physicians' Desk Reference (56th Edition) 2002, Montvale, NJ: Thompson PDR.